Andrey A. Dyachenko

Andrey A. Dyachenko

Auto-generated profile, based on publicly available information

Andrey A. Dyachenko

Northern State Medical University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Burdenko's Journal of Neurosurgery
Verified
Journal Article
Closed access
KKK. Kalyango
K. Kalyango
ADA.A. Dyachenko
A.A. Dyachenko
DBD.V. Bogdanov
D.V. Bogdanov
EPE.F. Potekhina
E.F. Potekhina
VMV.M. Merabishvili
V.M. Merabishvili
MVM.YU. Valkov
M.YU. Valkov
Распространенность и динамика отдельных морфологических вариантов нейроглиальных злокачественных новообразований головного мозга (ЗНО ГМ) (код С71 по МКБ-10) для популяции Российской Федерации неизвестна. ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить динамику заболеваемости ЗНО ГМ в 2000—2020 гг. на основе индивидуальных записей морфологически верифицированных случаев в канцер-регистре Архангельской области. МАТЕРИАЛ И МЕТОДЫ Рассчитаны «грубые» и стандартизованные по возрасту (СПВ) (стандарт ВОЗ 2000 г.) показатели заболеваемости ЗНО ГМ в период с 2000 по 2020 г. в целом по группе С70—С71 и с учетом морфологических подтипов опухоли. Заболеваемость морфологически верифицированной глиобластомой (ГБ) детально оценена с учетом пола, возраста, места проживания. Для оценки динамики и значимости линейных трендов использовали сегментированный регрессионный анализ. РЕЗУЛЬТАТЫ Всего за период с 2000 по 2020 г. выявлено 1699 случаев ЗНО ГМ, морфологическая верификация получена у 1289 (76%) больных, из них у 467 (27%), 92 (5%) и 307 (18%) выявлены ГБ, анапластические глиомы G3 и глиомы G2 соответственно. Доля ГБ и анапластических глиом возросла с 23,4% и 3,9% в 2000 г. до 55,3% и 9,2% в 2020 г. соответственно. На фоне снижения СПВ показателей для всей группы С71 после 2015 г. с 5,2 до 3,2 случая на 100 тыс. населения (ежегодная убыль 7,1%) заболеваемость ГБ монотонно возрастала — с 1,0 до 2,1 случая на 100 тыс. населения (ежегодный прирост 6,2%). Не выявлены различия в заболеваемости между мужчинами и женщинами. Уровни СПВ показателей заболеваемости были на 50—70% выше среди сельского населения. ЗАКЛЮЧЕНИЕ Выявлен статистически значимый рост заболеваемости глиобластомой — более чем в 2 раза за последние 20 лет, связанный, вероятно, с улучшением диагностики и регистрации этого заболевания. Требуется углубленный анализ заболеваемости и выживаемости при редких опухолях нейроглии.

27 December 2022 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
ЛВЛ. Е. Валькова
Л. Е. Валькова
ADA. A. Dyachenko
A. A. Dyachenko
VMV. M. Merabishvili
V. M. Merabishvili
DBD. V. Bogdanov
D. V. Bogdanov
ABA. V. Berezin
A. V. Berezin
MVM. Yu. Valkov
M. Yu. Valkov
Background. During the COVID-19 pandemic, annual adult check-ups have been postponed, resulting in cancer screening disruption.The aim of the study was to evaluate changes in the incidence and stage distribution of malignancies included in the screening program during the COVID-19 pandemic using the Arkhangelsk Regional Cancer Registry (ARRC).Material and Methods. We assessed the changes of the incidence rates and stage distribution for the colon, rectum, lung, breast, cervix, uterine body, ovary, prostate and kidney cancers over the periods 2018–19 and 2020–21. Results. A total of 12354 cases with 9 cancers were selected: 6680 for the period 2018–19 and 5674 (-15.1 %) for the period 2020-21. The most significant decrease in crude and age-standardized incidence rates was registered in patients with lung (-18.0–18.1 %), rectum (-25.1–25.9 %) and cervix (-33.6–36.9 %) cancers, p˂0.001. The decrease was not significant in patients with breast, uterine body, and kidney cancers. The proportion of patients with stage I decreased in lung cancer (-20.0 %, from 14.8 % to 11.8 %), rectum (-20.2 %, from 20.9 % to 16.7 %), and uterine cervix (-37.1 %, from 53.2 % to 33.5 %). In prostate and kidney cancers, the proportion of patients with stage I increased by 30 % (from 19.5 % to 25.4 %) and 17.6 % (from 45.9 % to 54.0 %), respectively. A significant reduction in the proportion of early stages during the COVID-19 pandemic was observed in lung and cervical cancer.Conclusion. Postponed health checkups due to COVID-19 pandemic disruptions have led to substantial reductions in new cancers being diagnosed, mainly for cervical, lung, colon and rectal cancers. No significant changes were observed for other cancers. Further analysis of mortality and survival of cancer patients is required.

12 December 2024 in Ekologiya cheloveka (Human Ecology)
Verified
Journal Article
Open access
PDF file
MVMikhail Yu. Valkov
Mikhail Yu. Valkov
AGAndrej M Grjibovski
Andrej M Grjibovski
AKAlexander V. Kudryavtsev
Alexander V. Kudryavtsev
MBMaxim A. Bogdanov
Maxim A. Bogdanov
DBDmitriy V. Bogdanov
Dmitriy V. Bogdanov
ГАГомболевский Виктор Александрович
Гомболевский Виктор Александрович
Aim: To present the ARILIS study aimed at assessing the use of artificial intelligence to analyze chest computed tomography (CT) data to predict and prevent non-cancer mortality in patients with cancer. Material and methods: This cohort study will include patients with cancer diagnosed in the Arkhangelsk region (AR) within the 2019–2023 period. The COVID-19 patients with pneumonia, patients with general medical conditions, and the population of the Know Your Heart Study are planned to be enrolled as control groups. To detect and quantify the CT signs of the cardiovascular, pulmonary, and bone disorders, the thoracic СT scans of all the subjects will be processed using the multi-targeted AI algorithm provided by the IRA Labs company. From the date of processing of the thoracic CT scans using the multi-targeted AI algorithm, the study subjects will be followed for new clinical diagnoses and all-cause mortality. Expected results: T he study will determine the prevalence of CT signs of the cardiovascular, pulmonary, and bone disorders in patients with cancer compared with the Know Your Heart Study population sample. It will also assess the incidence of cardiovascular, pulmonary, and bone events and all-cause mortality in patients with cancer compared with control groups, explore the potential of the IRA Labs’ multi-targeted AI algorithm in the assessment and reclassification of assessed risks in patients with cancer, and provide a software product for using mtIA in healthcare practice.

2 September 2023 in Voprosy onkologii
Verified
Journal Article
Open access
АААнна Агаева
Анна Агаева
ДГДмитрий Громов
Дмитрий Громов
ОЧОльга Чемакина
Ольга Чемакина
АСАнастасия Светлакова
Анастасия Светлакова
ЛВЛюдмила Валькова
Людмила Валькова
МВМихаил Вальков
Михаил Вальков

25 June 2023 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
AAA. V. Agaeva
A. V. Agaeva
ASA. V. Svetlakova
A. V. Svetlakova
DGD. D. Gromov
D. D. Gromov
OCO. V. Chemakina
O. V. Chemakina
ЛВЛ. Е. Валькова
Л. Е. Валькова
MVM. Yu. Valkov
M. Yu. Valkov
Background. Breast cancer (BC) is the leading cancer in the world and in Russia. Epidemiological factors predicting breast cancer survival in Russia have not been studied enough. Aim. To evaluate the factors predicting survival in BC by the data of the Arkhangelsk Regional Cancer Registry in 2000–2020 and the survival during the COVID-19 pandemic Materials and methods. Data on all cases of Вс for 2000–2020 retrieved from the Arkhangelsk Regional Cancer Registry database. Cancer-specific survival was estimated using the Kaplan–Meier and the life tables method. The prognostic value of variables available in Arkhangelsk Regional Cancer Registry was assessed in Cox regression. Results. The final analysis included 9,089 cases of breast cancer. During the observation period, 2723 deaths from breast cancer were registered. The one-, five- and ten-year survival rates in the entire population were 91.6 %, 73.0 % and 64.0 %, respectively. In a multivariate analysis, the risk of death from BC increased by 2.9, 8.2, 21.3 and 6.8 at 2, 3, 4 and unknown stages; 2.1 times with the localization of the tumor in the area of the nipple and areola; by 33 % in ductal cancer compared with lobular cancer, by 1.8 and 2.6 times in those who received palliative treatment and did not receive treatment; by 33 % in women aged 80 years and older; by 22 % for those living in rural areas. In the period 2013–2019, the 5-year cancer-specific survival reached 79.1 %, which is 14 % and 6 % higher than in the periods 2000–2006 and 2007–2012. Survival rates have not declined during the COVID-19 pandemic. Conclusion. The risk of death from BC is increased in advanced stages, ductal morphology, localization in the nipple-areolar region, age over 80 years, and living in rural areas. During the COVID-19 pandemic BC survival did not worsen, but this requires further study.

29 June 2023 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
ASA. V. Svetlakova
A. V. Svetlakova
DGD. D. Gromov
D. D. Gromov
OCO. V. Chemakina
O. V. Chemakina
AAA. V. Agayeva
A. V. Agayeva
ЛВЛ. Е. Валькова
Л. Е. Валькова
MVM. Yu. Valkov
M. Yu. Valkov
Cancer of the corpus uteri (CCU) is one of the most common gynecological malignancies in high- and middleincome countries. The objective of the study was to evaluate the factors predicting survival in CCU patients over the period 2000-2021 using the data of population-based cancer registry of the Arkhangelsk region. Material and Methods. Cancer-specific survival (CSS) of patients with CCU for the period 2000-21 was evaluated using life tables and Kaplan-Mayer methods with a log-rank test. The Cox proportional hazards regression model was used to assess the effect of prognostic factors on survival time. Results. A total of 3272 cases were selected for the analysis. The 5-year survival rates improved from 70.6 % in 2000-04 to 75.6 % in 2015-19. In stage I, II, III, and IV CUN, the 5-year survival rates were 90.8 % (95 % CI 89.3-92.0 %), 71.1 (95 % CI 66.3-75.4 %), 46.7 (95 % CI 41.4-51.8 %), and 3.9 (95 % CI 1.5-7.5 %), respectively; p<0.001. In the multivariate regression model, for stage II, III, and IV CCU, the hazard ratios for death from cancer were respectively 2.69 (2.14-3.39), 5.73 (4.66-7.03), and 20.26 (16.13-25.44) compared to stage I. The risk of death from CCU was 2.0-2.7 times higher in patients with aggressive histological subtypes and sarcomas compared to that in patients with endometrioid adenocarcinoma; 2.0-2.8 times higher in patients older than 60 years compared to younger patients, and 1.3 times higher in rural patients compared to urban patients (p<0.05). There was no increase in the risk of death from CCU over the period of COVID-19 pandemic. Conclusion. In this population-based study, we have found that the survival of patients with CCU is significantly affected by age and place of residence, which may indicate a limited access of some patients to effective treatment and requires further analysis. No increased risk of death from CCU during the COVID-19 pandemic was found.